Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

ALISKIREN HEMIFUMARATE

ALISKIREN HEMIFUMARATE

Standard Dose
EQ 300MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ALISKIREN HEMIFUMARATE is listed in Drugs@FDA under application 206665 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ALISKIREN HEMIFUMARATE Form and strength TABLET;ORAL - EQ 300MG BASE Sponsor PH HEALTH Submission history Latest submission status date: 2023-05-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview ALISKIREN HEMIFUMARATE is listed in Drugs@FDA under application 206665 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ALISKIREN HEMIFUMARATE Form and strength TABLET;ORAL - EQ 300MG BASE Sponsor PH HEALTH Submission history Latest submission status date: 2023-05-19 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.